| Weight | 4 kg |
|---|---|
| Dimensions | 34.8 × 41 × 12.3 cm |
OneScreen 10 Panel Drug Cup (box of 25)
$377.50 + GST
The OneScreen 10 Panel Urine Drug Cup is a simple, cost-effective solution for rapid urine drug screening. Designed specifically for addiction treatment and clinical environments, the OneScreen cup screens for 10 common drugs of abuse and delivers preliminary results within just 5 minutes.
By providing immediate screening results onsite, organisations can reduce unnecessary laboratory testing costs while maintaining confidence in their testing programme. Samples that return a not-negative result can then be referred for confirmatory laboratory analysis as required.
The OneScreen 10 Panel Urine Drug Cup is intended for clinical, treatment and monitoring applications and is not independently verified to AS/NZS 4308:2023 standard workplace testing standards. For workplace drug testing, please view our Medix Pro-Split or MicroScreen2 urine drug screening cups.
The OneScreen 10 cup tests for:
- Amphetamine (AMP) 300 ng/mL
- Benzodiazepines (BZO) 200 ng/mL
- Cocaine (COC) 300 ng/mL
- Methamphetamine (MET) 300 ng/mL
- Opiates (OPI) 300 ng/mL
- Oxycodone (OXY) 100 ng/mL
- Cannabis (THC) 50 ng/mL
- Methadone (MTD) 300 ng/mL
- Methylphenidate (MPD) 300 ng/mL
- Buprenorphine (BUP) 10 ng/mL
The OneScreen 10 Panel Urine Drug Cup is commonly used by:
- Addiction treatment centres
- Opioid substitution and methadone treatment programmes
- Community alcohol and drug services
- Hospitals and emergency departments
- Rehabilitation services
- Correctional and custodial facilities
Product Features and Benefits
- 10-panel urine drug screen
- Results in approximately 5 minutes
- One-step testing procedure
- No specimen transfer required
- Built-in temperature strip
- Space for donor identification
- Results can be photographed for records
- Suitable for clinical and treatment settings
Packaging
Supplied in cartons containing 25 individually packaged testing cups.
Note: The OneScreen 10 Panel Urine Drug Cup provides preliminary screening results only. Not-negative results should be confirmed by laboratory analysis where required by policy or clinical protocols.